Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Squadron Master Fund LP and related parties report a significant ownership stake in Lipocine Inc. The group, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, reports beneficial ownership of 810,000 shares of Lipocine common stock, representing 9.8% of the outstanding shares, based on 8,244,253 shares outstanding as of May 6, 2026. Voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power. The reporting persons state that the Funds have the right to receive dividends and sale proceeds and expressly disclaim beneficial ownership under Rule 13d-4.
Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036. The options are subject to vesting: one-third of the shares vest on the one-year anniversary of August 3, 2027, and the remaining two-thirds vest monthly on a prorata basis over the following two years. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Lipocine Inc. filed an initial beneficial ownership report for Michael Grissinger, who is identified as a director but not an officer or ten percent owner. The filing reports no equity holdings or insider transactions for him at this time.
Lipocine Inc. reported Q2 2026 results highlighted by increased liquidity and ongoing investment in its development pipeline. As of June 30, 2026, it held $23.3 million in unrestricted cash, cash equivalents and marketable investment securities, up from $14.9 million at December 31, 2025. For the quarter, net loss was $2.6 million, or ($0.32) per diluted share, compared with a net loss of $2.2 million, or ($0.41) per diluted share, a year earlier. Royalty revenue from TLANDO was $190,099, versus $122,849 in Q2 2025.
For the first half of 2026, total revenue was $309,496, consisting entirely of TLANDO royalties, compared with $716,713 in the prior-year period, which included $500,000 of license revenue. Net loss for the six months was $6.3 million, or ($0.84) per diluted share, versus $4.1 million, or ($0.76) per share, in 2025, reflecting higher research and development expenses of $4.8 million tied primarily to the LPCN 1154 Phase 3 study and increased personnel costs, as well as modestly higher general and administrative expenses. Lipocine continues to advance an oral therapeutics pipeline including LPCN 1154 for postpartum depression and several candidates targeting major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms and prevention of preterm birth.
Lipocine Inc., a clinical‑stage biopharma company focused on oral hormone and CNS therapies, reported Q2 2026 revenue of $190,099, all from TLANDO royalties, and a net loss of $2.6 million (H1 2026 loss $6.3 million on $309,496 revenue). Operating expenses increased year to date versus 2025, mainly from higher research and development spending.
Cash and cash equivalents were $4.98 million with $18.29 million in marketable securities at June 30, 2026. After raising $13.5 million net through at‑the‑market share sales, management expects existing capital to fund operations through at least August 4, 2027, while still anticipating additional financing over the longer term. Growth is anchored in TLANDO licensing, including an $11.0 million Verity deal and UAE approval for TESTYRA, alongside a CNS pipeline where lead PPD candidate LPCN 1154 recently failed to meet its Phase 3 primary endpoint, prompting further analyses, a new trial, and an upcoming FDA meeting.
Lipocine Inc. expanded its Board of Directors to five members and appointed Michael J. Grissinger as a director, effective August 3, 2026. The board determined that he qualifies as an independent director under Nasdaq listing standards.
Upon joining, Grissinger receives an initial stock option grant to purchase 2,000 shares of Lipocine common stock and an annual non-employee director cash retainer of $55,000. He brings extensive business development and M&A experience from senior roles at Johnson & Johnson and prior work at Ciba-Geigy, and currently serves on several public biotech boards.
Lipocine describes a pipeline of orally delivered drug candidates, including programs in postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis, and preterm birth, alongside its FDA-approved oral testosterone product TLANDO. The company furnished a press release detailing the appointment and its strategic rationale.
Lipocine Inc. director and CEO Mahesh V. Patel received a new stock option grant as part of his compensation. He was awarded options to acquire 52,781 shares of Lipocine common stock at an exercise price of $2.49 per share, bringing his total stock option holdings reported in this filing to 227,214 options.
The grant is subject to vesting: one-third of the options will vest on June 29, 2027, and the remaining two-thirds will vest monthly on a prorated basis over the following two years. This structure is designed to tie his equity compensation to continued service and long-term performance.
Lipocine Inc. filed a report describing a virtual key opinion leader event held on June 12, 2026. The event focused on unmet medical needs in postpartum depression and reviewed the clinical profile of the company’s investigational product candidate LPCN 1154.
The related slide presentation was furnished as Exhibit 99.1 and is incorporated by reference. Lipocine notes that a link to the presentation is available on its corporate website, giving investors and clinicians access to the detailed discussion from the event.
Lipocine Inc. held its annual shareholder meeting on June 3, 2026 and approved the Sixth Amended and Restated 2014 Stock and Incentive Plan. The amendment raises individual award limits from 25,000 to 100,000 shares and increases available common stock awards by 400,000 shares, so the plan now authorizes up to 1,000,000 shares in total. Shareholders re-elected four directors and ratified Tanner LLC as independent registered public accountants for the fiscal year ending December 31, 2026. They also approved a say‑on‑pay advisory vote on executive compensation, the amended stock and incentive plan, and an adjournment proposal to continue soliciting votes on these matters.
Higuchi John W. reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director John W. Higuchi received a grant of derivative securities giving him the right to buy 1,764 shares of common stock at $2.19 per share. These rights vest 100% one year from the grant date and expire on June 3, 2036. Following this award, Higuchi holds rights to purchase a total of 13,290 shares of common stock.